| |
Radiofrequency catheter ablation - RFA
|
Emergency care
|
|---|
|
Diagnoses and patients
|
TotalN = 270
|
AVNRT n = 40
|
WPWn = 16
|
FATn=8
|
Atrial macro-reentryn = 4
|
AFLn = 16
|
AFn = 126
|
Ventricul ararrhythmian = 5
|
AFn = 55
|
|---|
|
Age mean (SD)
|
59.3(12.9)
|
54.6(13.1)
|
38.8(15.4)
|
54.3(17.5)
|
59.3(10.0)
|
59.1(15.3)
|
60.3(9.3)
|
60.6(13.0)
|
67.3(10.3)
|
|
GenderF/M(M %)
|
93/177(66)
|
23/17(43)
|
8/8(50)
|
5/3(38)
|
1/3(75)
|
3/13(81)
|
33/93(74)
|
0/5(100)
|
20/35(64)
|
|
Cohabitant/living alone(cohabit. %)
1
|
223/45(83)
|
35/5(88)
|
13/3(81)
|
7/1(88)
|
3/1(75)
|
14/2(88)
|
105/20(83)
|
4/1(8)
|
42/12(76)
|
|
Education
2
|
|
Elementary school certificate
|
26(10)
|
3(7.5)
|
1(6)
|
0
|
1(25)
|
0
|
10(8)
|
0
|
11(20)
|
|
Compulsory school certificate
|
71(26)
|
14(35)
|
2(13)
|
4(50)
|
0
|
2(13)
|
34(27)
|
0
|
15(27)
|
|
Upper secondary school certificate
|
96(36)
|
11(28)
|
9(56)
|
3(38)
|
3(75)
|
7(44)
|
44(35)
|
2(40)
|
17(31)
|
|
College/University degree
|
73(27)
|
11(28)
|
4(25)
|
1(13)
|
0
|
7(44)
|
36(29)
|
3(60)
|
11(20)
|
|
Medication
3
|
|
Class I(%)
|
46(17)
|
0
|
1(6)
|
0
|
0
|
0
|
38(30)
|
0
|
7(13)
|
|
Class II(%)
|
159(59)
|
16(40)
|
6(38)
|
3(38)
|
2(50)
|
10(63)
|
81(64)
|
2(40)
|
39(71)
|
|
Class III(%)
|
41(15)
|
4(10)
|
0
|
2(25)
|
2(50)
|
1(6)
|
27(21)
|
2(40)
|
3(6)
|
|
Class IV(%)
|
36(13)
|
1(3)
|
0
|
0
|
2(50)
|
0
|
24(19)
|
0
|
9(16)
|
|
Digitalis(%)
|
20(7)
|
0
|
1(6)
|
1(13)
|
0
|
1(6)
|
10(8)
|
1(20)
|
6(11)
|
- AVNRT = AV-Nodal reentry tachycardia, WPW = Wolff-Parkinson-White syndrome, FAT = focal atrial tachycardia, atrial macro-reentry, AFL atrial flutter, AF = atrial fibrillation, AF patients with out-patient visits in emergency room. Ventricular arrhythmia includes ventricular tachycardia and VES = Ventricular extra beats. RFA = radiofrequency ablation.
- 1 2 missing values.
- 2 4 missing values.
- 3 Here, medication is anti-arrhythmic medication where one patient can have more than one drug.
- Class I represents flecainide/propafenon, class II beta blockers, class III amiodarone/sotalol, and class IV calcium channel blockers.
